# EDGAR Filing Document

**Accession Number:** 0001279191
**File Stem:** 0001493152-26-004801
**Filing Date:** 2026-2
**Character Count:** 7981
**Document Hash:** 39bd1ccc78be844fc610b09a0e56fa34
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-004801.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001493152-26-004801

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dermata Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001853816
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92822
- **FILM NUMBER:** 26589373

**BUSINESS ADDRESS:**
- **STREET 1:** 3525 DEL MAR HEIGHTS RD., #322
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858)-223-0882

**MAIL ADDRESS:**
- **STREET 1:** 3525 DEL MAR HEIGHTS RD., #322
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROEHL GERALD T
- **CENTRAL INDEX KEY:** 0001279191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 10590 W OCEAN AIR DR
- **STREET 2:** STE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 8583145700

**MAIL ADDRESS:**
- **STREET 1:** 10590 W OCEAN AIR DR
- **STREET 2:** STE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 9)**

**Dermata Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, Par Value $0.0001 Per Share.**

*(Title of Class of Securities)*

**249845504**

*(CUSIP Number)*

**Gerald T. Proehl**<br>President and Chief Executive Officer,<br>3525 Del Mar Heights Rd., #322<br>San Diego CA 92130<br>(973) 701-2431

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/29/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **249845504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PROEHL GERALD T** | Name of reporting person<br>**PROEHL GERALD T** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**694576.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**694576.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**694576.00** | Aggregate amount beneficially owned by each reporting person<br>**694576.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.6%** | Percent of class represented by amount in Row (11)<br>**19.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, Par Value $0.0001 Per Share.

**(b) Name of Issuer:**
Dermata Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3525 Del Mar Heights Rd., #322, San Diego, CA, 92130

This Amendment No. 9 (this "Amendment") amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on August 27, 2021, as amended on April 25, 2022, January 13, 2023, March 30, 2023, January 23, 2025, February 13, 2025, April 3, 2025, April 7, 2025, and January 8, 2026 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Schedule 13D and the information set forth in or incorporated by reference in Item 2 and Item 3 of the Schedule 13D is hereby incorporated by reference in its entirety into this Item 5.

As of the date hereof, Mr. Proehl may be deemed to beneficially own an aggregate of 694,576 shares of Common Stock reported herein as follows: (i) 24 shares of Common Stock and stock options to purchase 1,763 shares of Common Stock held directly by Mr. Proehl; (ii) 79,950 shares of Common Stock and 11 shares of Common Stock underlying warrants that are exercisable within sixty (60) days of the date hereof held by Proehl Investment Ventures LLC ("PIV"); and (iii) 612,828 shares of Common Stock held in the aggregate by certain trusts (the "Trusts") for which Mr. Proehl is trustee.

Mr. Proehl's reported ownership excludes (i) 41,070 shares of Common Stock underlying stock options held by Mr. Proehl that will not vest as to such shares of Common Stock within sixty (60) days of the date hereof; and (ii) 78,740 shares of Common Stock underlying warrants that are not exercisable within sixty (60) days of the date hereof. The warrants reported in (ii) above are not exercisable until the Issuer obtains stockholder approval of the transaction in which such warrants were issued. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Proehl may be deemed to beneficially own 19.6% of the Common Stock of the Issuer outstanding as of the date hereof (based on 3,549,393 shares of Common Stock outstanding as of January 29, 2026 based on information obtained from the Issuer).

**(b)**
As of the date hereof, Mr. Proehl may be deemed to be the beneficial owner of an aggregate of 694,576 shares of Common stock, all of which he has sole voting and dispositive power.

**(c)**
Since Amendment No. 8 to this Schedule 13D (filed on January 8, 2026), there were no purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Person or any person or entity for which the Reporting Person possess voting or dispositive control over the securities thereof.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PROEHL GERALD T

**Signature:** /s/ Gerald T. Proehl

**Name/Title:** Gerald T. Proehl

**Date:** 02/02/2026